{"id":"W2465799764","doi":"10.1111/bjd.14871","title":"Topical tofacitinib for atopic dermatitis: a phase <scp>II</scp> a randomized trial","year":2016,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Probity Medical Research; Innovaderm (Canada)","funders":"Pfizer","keywords":"Tofacitinib; Eczema Area and Severity Index; Tolerability; Medicine; Janus kinase inhibitor; Atopic dermatitis; Adverse effect; Randomized controlled trial; Clinical endpoint; Internal medicine; Pharmacodynamics; Dermatology; Pharmacokinetics; Onset of action; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003001848,0.0001952311,0.00159583,0.000185615,0.0001798929,0.00003006318,0.0002038341,0.0002996481,0.0001197016],"category_scores_gemma":[0.005841583,0.000151733,0.0007932162,0.00008680388,0.000454036,0.0002187829,0.00004775155,0.0002439364,0.00001798137],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003485198,"about_ca_system_score_gemma":0.0003237695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000031451,"about_ca_topic_score_gemma":0.000004772503,"domain_scores_codex":[0.9974054,0.0003920701,0.001287053,0.000211357,0.0002470758,0.0004570506],"domain_scores_gemma":[0.9964821,0.002089331,0.0005443761,0.0001720788,0.0003615455,0.0003505955],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3345855,0.003706953,0.00448599,0.0004730819,0.002055131,0.03716597,0.0004534785,1.445041e-7,0.0004043368,0.003857856,0.516909,0.09590261],"study_design_scores_gemma":[0.733708,0.0003347938,0.0003941745,0.0004122136,0.0004553757,0.2005355,0.00005731506,0.00001178688,0.002538472,0.003757763,0.05772696,0.00006759215],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9713897,0.006445853,0.009666777,0.009321663,0.001010006,0.001193084,0.00006856734,0.000046867,0.0008574738],"genre_scores_gemma":[0.9947352,0.0008753837,0.001134983,0.002005843,0.0004475793,0.000121375,0.00001467951,0.00002450442,0.000640398],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.459182,"threshold_uncertainty_score":0.6993343,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01635605518526289,"score_gpt":0.300221266251213,"score_spread":0.2838652110659501,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}